Drug intelligence / Profile preview

allograft particles + becaplermin

Development stage: Unknown
Lead developer: Wright Medical Group
Modality: Recombinant Proteins and Enzymes, Peptides
Administration: Implant

Overview

Allograft particles + rhPDGF is an investigational combination product used for lateral ridge augmentation in patients with deficient alveolar bone ridges prior to dental implant placement. The product consists of mineralized corticocancellous bone allograft particles (freeze-dried bone) that are hydrated with recombinant human platelet-derived growth factor-BB (rhPDGF-BB), also known as becaplermin. rhPDGF-BB is a potent biologic growth factor that stimulates cell proliferation, chemotaxis, and angiogenesis by binding to PDGF receptors (PDGFRA and PDGFRB) on mesenchymal cells, including osteoblasts and periodontal ligament cells. This combination aims to enhance bone regeneration and healing compared to conventional saline-hydrated allografts. It is typically applied in conjunction with a resorbable collagen barrier membrane. The University of Alabama at Birmingham is currently evaluating this combination in a randomized clinical trial.

Brand names: GEM 21SGEM21SGEM-21S
Other names: rhPDGF-BB + allograftrecombinant human platelet-derived growth factor-BB + mineralized corticocancellous bone allograft

Targets

PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)

Beyond the preview

Go deeper on allograft particles + becaplermin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on allograft particles + becaplermin.

Explore the full profile